Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy

This randomized clinical trial evaluates the use of transdermal cannabidiol vs placebo for adults with drug-resistant focal epilepsy.

• Publication year

  2022

• Venue

  JAMA Network Open

• Publication date

  2022-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamanetworkopen.2022.20189PMID 35802375PMCID 9270696
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial.

  2021cited by this paper
• Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex

  2020cited by this paper
• Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.

  2019cited by this paper
• Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects

  2019cited by this paper
• Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study

  2019cited by this paper
• Cannabis for the Treatment of Epilepsy: an Update

  2018cited by this paper
• Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

  2018cited by this paper
• Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

  2018cited by this paper
• Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?

  2017cited by this paper
• Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study

  2017cited by this paper
• Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP)

  2017cited by this paper
• Interactions between cannabidiol and commonly used antiepileptic drugs

  2017cited by this paper
• Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.

  2017cited by this paper
• Trial of Cannabidiol for Drug‐Resistant Seizures in the Dravet Syndrome

  2017cited by this paper
• Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome

  2017cited by this paper
• Cannabidiol and Epilepsy: Sifting, Winnowing and Buzz

  2016cited by this paper
• A randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial‐onset seizures

  2015cited by this paper
• Cannabinoids in the Treatment of Epilepsy.

  2015cited by this paper
• Randomized phase III study 306

  2012cited by this paper
• The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.

  2011cited by this paper
• Lacosamide as adjunctive therapy for partial‐onset seizures: A randomized controlled trial

  2010cited by this paper
• Human Cannabinoid Pharmacokinetics

  2007cited by this paper
• Cannabidiol: An Overview of Some Pharmacological Aspects

  2002cited by this paper
• Early identification of refractory epilepsy.

  2000cited by this paper
• The Medical Dictionary for Regulatory Activities (MedDRA)

  1999cited by this paper
• Seizure Disorders: The Changes With Age

  1992cited by this paper
• Controlled clinical trial of cannabidiol in Huntington's disease.

  1991cited by this paper
• Hypnotic and Antiepileptic Effects of Cannabidiol

  1981cited by this paper
• Chronic administration of cannabidiol to healthy volunteers and epileptic patients.

  1980cited by this paper
• F1000Research

  year unknowncited by this paper

• Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.

  2026cites this paper
• Medical cannabis and the hype cycle: Clinical evidence and future directions.

  2025cites this paper
• Structural and dynamic mechanisms of cannabinoid receptors.

  2025cites this paper
• Clinical practice guidelines for the administration of third-generation anti-seizure medications.

  2025cites this paper
• Exploring Cannabidiol’s Role in Regenerative Medicine: Focus on Neural and Skeletal Tissues

  2025cites this paper
• In Vivo and In Vitro Crosstalk Among CBD, Aβ, and Endocannabinoid System Enzymes and Receptors.

  2025cites this paper
• Cannabis derivatives and their synthetic analogs for treatment-resistant epilepsy: A systematic review and meta-analysis.

  2025cites this paper
• Cannabidiol in Drug-Resistant Epilepsy and Beyond

  2025cites this paper
• The use of cannabidiol as adjunctive therapy in adult patients with drug-resistant epilepsy: a systematic review and meta-analysis

  2025cites this paper
• Transdermal Delivery of Cannabidiol for the Management of Acute Inflammatory Pain: A Comprehensive Review of the Literature

  2024cites this paper
• Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis.

  2024cites this paper
• Navigating neurological disorders: harnessing the power of natural compounds for innovative therapeutic breakthroughs

  2024cites this paper
• Is adjunctive Cannabidiol effective in controlling seizures for adult patients with Lennox-Gastaut Syndrome? - A single centre long term follow up study.

  2024cites this paper
• Therapeutic potential of cannabidiol in depression.

  2024cites this paper
• Evaluation of the effect of cannabidiol administration with and without nonsteroidal anti-inflammatory drugs in dogs with mobility disorders: a prospective, double-blind, crossover, placebo-controlled study

  2024cites this paper
• Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders.

  2024cites this paper
• Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review

  2023cites this paper
• Efficacy and Safety of Cannabis Transdermal Patch for Alleviating Psoriasis Symptoms: Protocol for a Randomized Controlled Trial (CanPatch)

  2023cites this paper
• Adverse Events of Cannabidiol Use in Patients With Epilepsy

  2023cites this paper
• Cannabidiol goes nuclear: The role of PPARγ.

  2023cites this paper
• High-purified cannabidiol efficacy and safety in a cohort of adult patients with various types of drug-resistant epilepsies.

  2023cites this paper
• Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies

  2023cites this paper
• Therapeutic Strategies to Ameliorate Neuronal Damage in Epilepsy by Regulating Oxidative Stress, Mitochondrial Dysfunction, and Neuroinflammation

  2023cites this paper
• A UTILIZAÇÃO DO CANABIDIOL NO TRATAMENTO DE DOENÇAS NEUROLÓGICAS

  2023cites this paper
• Long-term efficacy and adverse effects of cannabidiol in adjuvant treatment of drug-resistant epilepsy: a systematic review and meta-analysis

  2023cites this paper
• Adjunctive Use of Cannabidiol: A Joint Action to Patch Up Drug-Resistant Epilepsy

  2023cites this paper
• Error in Nonauthor Collaborators List

  2022cites this paper
• Error in Abstract and Visual Abstract

  2022cites this paper